Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

× No keyword cloud information.

9 in total

Review 1. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors: Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal: Curr Hematol Malig Rep Date: 2020-02 Impact factor: 3.952

Review 2. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors: Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal: Antioxid Redox Signal Date: 2017-05-15 Impact factor: 8.401

Review 3. Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy.

Authors: Mohanad Gabani; Diana Castañeda; Quynh My Nguyen; Soo-Kyoung Choi; Cheng Chen; Ayesha Mapara; Adam Kassan; Alexis A Gonzalez; Tahsin Khataei; Karima Ait-Aissa; Modar Kassan
Journal: Cureus Date: 2021-09-22

4. Cardiotoxicity associated with targeted cancer therapies.

Authors: Z I Chen; D I Ai
Journal: Mol Clin Oncol Date: 2016-03-03

Review 5. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.

Authors: Shelby D Reed; Kevin J Anstrom; Yanhong Li; Kevin A Schulman
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

Review 6. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

Authors: Javid J Moslehi; Michael Deininger
Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544

7. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

Authors: Tariq I Mughal; Andrew Schrieber
Journal: Biologics Date: 2010-12-02

Review 8. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors: J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal: Leukemia Date: 2016-04-28 Impact factor: 11.528

9. Imatinib Mesylate Induces Necroptotic Cell Death and Impairs Autophagic Flux in Human Cardiac Progenitor Cells.

Authors: Robert Walmsley; Derek S Steele; Georgina M Ellison-Hughes; Sotiris Papaspyros; Andrew J Smith
Journal: Int J Mol Sci Date: 2022-10-05 Impact factor: 6.208

9 in total